EGFR and neoplasm: In another large cohort, 100 of 1173 (8.53%) NSCLC patients’ tumor were identified as RDAA positive that does not have known and targetable EGFR/ALK/ROS1 mutation or rearrangement (Fig. 4e, Supplementary Tables 3–6).